证券代码：600488 证券简称：津药药业 编号：2025-029 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司 2025 年 4 月 30 日，津药药业股份有限公司（以下简称"公司"）收到 天津市市场监督管理委员会下发的《行政处罚决定书》（津市监垄处〔2025〕 1 号），现将相关情况公告如下： 关于收到行政处罚决定书的公告 一、决定书主要内容 天津市市场监督管理委员会认为，公司与具有竞争关系的其他经营者， 就地塞米松磷酸钠原料药所实施的一系列行为，违反了《反垄断法》第十 七条第（一）项的规定，属于达成并实施"固定或者变更商品价格"垄断 协议的行为，应当依据《反垄断法》第五十六条的规定依法追究法律责任。 根据《反垄断法》第五十六条第一款、第五十九条，综合考虑公司违 法行为的性质、程度、持续时间、消除违法后果的情况、积极进行整改等 因素，天津市市场监督管理委员会责令公司停止违法行为，并作出行政处 罚如下：（一）没收违法所得 42,764,400.00 元；（二）并处 2023 年度销售 额 8%的 ...

Core Viewpoint - The company has reported its first-quarter financial results for 2025, highlighting significant developments in product approvals and strategic initiatives aimed at enhancing operational efficiency and shareholder returns [12][28]. Financial Data - The company achieved a revenue of 3.215 billion yuan and a net profit attributable to shareholders of 133 million yuan in 2024 [12]. - The company plans to distribute a cash dividend of 0.98 yuan per 10 shares for the 2024 fiscal year, totaling approximately 107 million yuan, maintaining a cash dividend ratio of 80.18% [15]. Product Approvals and Market Expansion - The company received approval for the active pharmaceutical ingredient (API) Fumarate Formoterol and the inhalation solution from the National Medical Products Administration, which is expected to enhance its market presence [5]. - The company’s Dexamethasone Sodium Phosphate API has been approved for sale in Brazil, which will aid in expanding its international market footprint [5]. - The company obtained a production license for special dietary foods covering 26 amino acids, enhancing its operational capabilities [5]. Research and Development - In 2024, the company invested 248 million yuan in R&D, representing 7.7% of its main business revenue, and achieved significant milestones in drug approvals [16]. - The company plans to focus on six key areas, including ophthalmology and dermatology, to enhance its product pipeline and market competitiveness [17]. Compliance and Governance - The company is committed to enhancing its compliance management systems and has implemented various measures to improve operational efficiency and risk management [18][22]. - The company has revised its governance documents to align with regulatory requirements and improve its response to public sentiment [22]. Investor Relations - The company emphasizes the importance of information disclosure and has actively engaged with investors through various channels, including regular reports and investor education initiatives [20][21]. - The company has received a B-level rating for information disclosure from the Shanghai Stock Exchange, reflecting its commitment to transparency [20].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）于2025年4月28日召 开公司第九届董事会第十六次会议及第九届监事会第十二次会议，分 别审议通过了《关于计提减值准备的议案》。具体情况如下： 一、资产减值准备的计提概况 为了更加客观、公允地反映公司2025年3月31日的财务状况以及 2025年第一季度的经营成果，根据《企业会计准则》相关规定和公司 会计政策，基于谨慎性原则，公司对相关资产进行减值测试，本期计 提各项减值准备共计2,174.22万元，收回或转回328.40万元，转销 1,800.95万元。具体如下： 证券代码：600488 证券简称：津药药业 编号：2025-026 津药药业股份有限公司 关于计提减值准备的公告 单位：万元 | 序 号 | 类别 | 本期计提 | 本期收回/转回 | 本期转销 | | --- | --- | --- | --- | --- | | 1 | 应收账款坏账准备 | 26.86 | 0.00 | 0.00 | | 2 | 其他应收款坏账准备 ...

证券代码：600488 证券简称：津药药业 编号：2025-027 津药药业股份有限公司 第九届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）第九届监事会第十二次会 议于 2025 年 4 月 28 日以通讯表决的方式召开。会议由监事会主席赵炜 先生主持，应参加表决监事 3 人，实际表决监事 3 人。会议符合《公司 法》和《公司章程》的有关规定。会议经过审议，与会监事全票通过如 下提案： 特此公告。 津药药业股份有限公司监事会 2025 年 4 月 28 日 1 / 1 1.审议通过公司《2025 年第一季度报告》 公 司 《 2025 年 第 一 季 度 报 告 》 详 见 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）同日披露的公告。 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 2.审议通过关于计提减值准备的议案 计提减值准备事项的决策程序合法、依据充分，计提符合企业会计 准则等相关规定，公允地反映了公司的资产 ...

证券代码：600488 证券简称：津药药业 编号：2025-025 公司《2025年第一季度报告》详见上海证券交易所网站（www.sse.com.cn） 同日披露的公告。此议案在提交董事会审议前，已经公司董事会审计与风 险控制委员会审议通过。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 2.审议通过关于计提减值准备的议案 公司依据实际情况计提减值准备，符合《企业会计准则》和公司财务 管理制度的相关规定，公允地反映了公司的资产状况，同意公司本次计提 减值准备方案。具体内容详见上海证券交易所网站（www.sse.com.cn）同日 披露的公告。 津药药业股份有限公司 第九届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）第九届董事会第十六次会议 于 2025 年 4 月 28 日以通讯方式召开。本次会议的通知已于 2025 年 4 月 18 日以电子邮件的方式送达公司各位董事、监事和高管人员。会议应参加表 决董事 9 人，实际表决董事 9 人。会议 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 785,765,994.13, a decrease of 9.03% compared to CNY 863,769,688.70 in the same period last year[4] - Net profit attributable to shareholders was CNY 58,050,125.92, showing a slight increase of 0.07% from CNY 58,012,016.03 year-on-year[4] - Total operating revenue for Q1 2025 was ¥785,765,994.13, a decrease of 9.05% compared to ¥863,769,688.70 in Q4 2024[19] - Net profit for Q1 2025 increased to ¥75,460,172.70, compared to ¥72,482,506.08 in Q4 2024, representing a growth of 3.93%[19] - The company’s total comprehensive income for the period was 75,907,038.19 RMB, compared to 73,365,945.30 RMB in the previous period, reflecting a growth of approximately 2.1%[20] - Basic and diluted earnings per share remained stable at 0.053 RMB per share for both Q1 2025 and Q1 2024[20] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -10,502,031.63, a decline of 120.37% compared to CNY 51,548,996.07 in the previous year, primarily due to an increase in accounts receivable and a decrease in sales collections[5] - In Q1 2025, the company reported a net cash flow from operating activities of -10,502,031.63 RMB, a decrease from 51,548,996.07 RMB in Q1 2024[22] - The company incurred total operating cash outflows of 637,404,364.07 RMB in Q1 2025, compared to 782,620,253.43 RMB in Q1 2024[23] - The net cash flow from financing activities was 128,961,037.93 RMB in Q1 2025, a significant improvement from -37,859,927.73 RMB in Q1 2024[24] - The company reported a decrease in cash inflows from operating activities, totaling 626,902,332.44 RMB in Q1 2025, down from 834,169,249.50 RMB in Q1 2024[23] - The cash and cash equivalents at the end of Q1 2025 increased to 702,801,334.96 RMB from 698,284,895.13 RMB at the end of Q1 2024[24] Assets and Liabilities - Total assets increased by 3.16% to CNY 5,878,076,844.70 from CNY 5,698,286,373.15 at the end of the previous year[4] - Total liabilities as of March 31, 2025, were ¥1,914,597,896.85, compared to ¥1,812,422,293.56 at the end of 2024, an increase of 5.67%[15] - The company's total assets reached ¥5,878,076,844.70 as of March 31, 2025, up from ¥5,698,286,373.15 at the end of 2024, an increase of 3.16%[14] - The company's equity attributable to shareholders increased to ¥3,117,551,908.66 as of March 31, 2025, compared to ¥3,057,347,087.18 at the end of 2024, a growth of 1.97%[15] Operational Developments - The company received approval for the raw material drug Fu-Ma-Suan-Fu-Mo-Tuo and the inhalation solution, which is expected to enhance its market presence and performance[10] - The company obtained approval from the Brazilian health authority for the raw material drug Dexamethasone Sodium Phosphate, facilitating market expansion in Brazil[10] - The company received its first production license for special dietary foods covering 26 amino acids, enhancing its operational capabilities[10] - The company passed the FDA cGMP inspection, providing a solid foundation for further international market expansion[10] - The company completed the registration of Naloxone Hydrochloride Injection, enriching its product portfolio[10] - The company is managing a 55.5222% stake in Tianjin Xinda Pharmaceutical Co., Ltd., enhancing its strategic investments[11] Inventory and Receivables - Accounts receivable increased to ¥426,084,165.89 in Q1 2025, compared to ¥291,238,382.36 in Q4 2024, marking a significant rise of 46.2%[13] - Inventory levels were reported at ¥665,055,904.34 as of March 31, 2025, slightly up from ¥651,915,382.71 at the end of 2024, an increase of 2.0%[13] - Short-term borrowings increased to ¥125,711,648.86 in Q1 2025 from ¥108,576,306.93 in Q4 2024, reflecting a rise of 15.5%[14]

Financial Performance - The company's basic earnings per share (EPS) for Q1 2025 remained unchanged at 0.0530 CNY compared to Q1 2024, but decreased from 0.0620 CNY in Q1 2023 [1] - The net profit for Q1 2025 was 0.58 billion CNY, consistent with Q1 2024, but down from 0.67 billion CNY in Q1 2023 [1] - Operating revenue for Q1 2025 was 7.86 billion CNY, a decrease of 9.03% from 8.64 billion CNY in Q1 2024 and down from 9.91 billion CNY in Q1 2023 [1] - The return on equity (ROE) for Q1 2025 was 1.88%, a decline of 3.09% from 1.94% in Q1 2024 and down from 2.24% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 65,344.49 million shares, accounting for 59.85% of the circulating shares, with an increase of 210.31 million shares from the previous period [2] - Tianjin Pharmaceutical Group Co., Ltd. remains the largest shareholder with 55,453.01 million shares, representing 50.79% of total share capital, unchanged from the previous report [2] - Hong Kong Central Clearing Limited increased its holdings by 324.11 million shares to 1,893.56 million shares, now holding 1.73% of total share capital [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]

证券代码：600488 证券简称：津药药业 编号：2025-028 津药药业股份有限公司 关于 "提质增效重回报" 2024 年度评估报告 暨 2025 年度行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为践行"以投资者为本"的理念，积极响应上海证券交易所 《关于开展沪市公司"提质增效重回报"专项行动的倡议》，承 担起高质量发展和提升自身投资价值的主体责任，津药药业股份 有限公司（以下简称"公司"）于 2024 年 10 月 30 日制定并发 布了 2024 年度"提质增效重回报"行动方案。 2024 年，公司依据行动方案积极开展并落实相关工作，通 过实施一系列具体措施取得了一定成效，公司经营质量进一步提 升，股东权益得到有效保障。现将 2024 年度"提质增效重回报" 行动方案实施效果的评估情况暨 2025 年度"提质增效重回报" 行动方案报告如下： 一、聚焦主业发展，优化经营新效能 2024 年是公司发展历程中充满挑战与机遇的一年，面对严 峻复杂的国内外市场环境，公司遵循"组织深度优化、稳销量、 保 ...

Policy Developments - Seven departments, including the Ministry of Industry and Information Technology, issued the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)", emphasizing the integration of artificial intelligence across the pharmaceutical supply chain [1] Drug and Device Approvals - Kangtai Biological announced that its subsidiary Minhai Biological's application for the marketing authorization of an adsorbed tetanus vaccine has been accepted by the National Medical Products Administration [2] - Hendi Pharmaceutical received approval for the marketing application of arginine ibuprofen, a non-steroidal anti-inflammatory drug with superior solubility and faster absorption compared to regular ibuprofen [3] - Tianyao Pharmaceutical's subsidiary obtained a drug registration certificate for injectable hydrocortisone sodium succinate, used for critical conditions such as allergic shock and severe adrenal insufficiency [4] Financial Reports - Wantai Biological reported a net loss of 52.78 million yuan in Q1 2025, with revenue of 401 million yuan, a year-on-year decline of 46.76%, primarily due to market adjustments and government procurement impacts [5] - Heng Rui Pharmaceutical's Q1 2025 report showed a revenue of 7.206 billion yuan, a year-on-year increase of 20.14%, and a net profit of 1.874 billion yuan, up 36.9%, largely due to a licensing payment from IDEAYA [6] - Kingstone Pharma reported a revenue of 291 million yuan in Q1 2025, down 19.65%, with a net profit of 62.85 million yuan, a decrease of 30.02% [8] - Baijun Medical achieved a revenue of 100 million yuan in Q1 2025, a 31.3% increase, with a net profit of 32.50 million yuan, up 290.69%, driven by stable sales of existing products and successful new product launches [9] Capital Market Activities - Tonghe Pharmaceutical plans to invest 11 million yuan to increase its stake in Hangzhou Boya Biomedical Co., Ltd., raising its ownership from 16.34% to 24.93% [10] - Chengyuan Biotechnology announced the completion of several million yuan in equity financing, aimed at upgrading its gene synthesis technology platform [11] Industry Developments - Zhang Wenhong's team announced significant progress in developing a broad-spectrum antiviral drug for monkeypox, which is set to enter clinical approval stages [12] - Qianxin Biotechnology signed a licensing agreement with Caldera Therapeutics for its long-acting dual antibody QX030N, granting global exclusive rights for development and commercialization [13] Public Sentiment Alerts - Weiming Pharmaceutical announced that its important subsidiary, Tianjin Weiming, was suspended from production and sales, which could trigger further risk warnings if production does not resume within three months [14]

精测电子：2024年净亏损9759.85万元 4月24日晚，精测电子（300567）发布2024年年度报告，公司2024年实现营业收入25.65亿元，同比增长 5.59%；实现归属于上市公司股东的净亏损9759.85万元，同比由盈转亏；基本每股收益为亏损0.35元/ 股。 神剑股份：2024年净利润同比增长32.29% 拟10派0.5元 4月24日晚，神剑股份（002361）发布2024年年度报告，公司2024年实现营业收入24.18亿元，同比下降 5.97%；实现归属于上市公司股东的净利润3365.07万元，同比增长32.29%；基本每股收益为0.0354元/ 股。公司拟向全体股东每10股派发现金红利0.5元（含税）。 资料显示，神剑股份成立于2002年4月，专业从事聚酯树脂系列产品的生产销售。 所属行业：基础化工–塑料–合成树脂 资料显示，精测电子成立于2006年4月，主营业务为显示、半导体、新能源检测系统的研发、生产与销 售。 所属行业：机械设备–通用设备–仪器仪表 经纬股份：2024年净利润同比下降36.76% 拟10派1元 4月24日晚，经纬股份（301390）发布2024年年度报告，公司2024年 ...